Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

BACKGROUND: Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial. METHODS: The aim of this retrospective multicenter study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortellini, Alessio, Vitale, Maria G., De Galitiis, Federica, Di Pietro, Francesca R., Berardi, Rossana, Torniai, Mariangela, De Tursi, Michele, Grassadonia, Antonino, Di Marino, Pietro, Santini, Daniele, Zeppola, Tea, Anesi, Cecilia, Gelibter, Alain, Occhipinti, Mario Alberto, Botticelli, Andrea, Marchetti, Paolo, Rastelli, Francesca, Pergolesi, Federica, Tudini, Marianna, Silva, Rosa Rita, Mallardo, Domenico, Vanella, Vito, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857130/
https://www.ncbi.nlm.nih.gov/pubmed/31730009
http://dx.doi.org/10.1186/s12967-019-02132-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857130/
https://www.ncbi.nlm.nih.gov/pubmed/31730009
http://dx.doi.org/10.1186/s12967-019-02132-x

Ejemplares similares